Dianthus Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
-8.13 | 33.49 | -124.28% | -2.05 | +295.7% |
| P/S |
|
114.88 | 129.83 | -11.52% |
|
|
| P/BV |
|
2.03 | 260.15 | -99.22% |
|
|
| P/FCF |
|
-8.82 | -180.12 | -95.1% |
|
|
| Ev/Ebitda |
|
-6.85 | -28.84 | -76.25% |
|
|
| Ev/S |
|
111.46 | 548.04 | -79.66% |
|
|
| Ev/FCF |
|
-8.88 | -289.87 | -96.94% |
|
|
| E/P |
|
-0.12 | 0.0228 | -640.12% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-1627.14 | -375.54 | 333.28% | -1406.83 | +15.66% |
| ROE |
|
-32.6 | 106.63 | -130.57% |
|
|
| ROA |
|
-30.71 | -2.32 | 1226.35% |
|
|
| ROIC |
|
0 | 0.83 | -100% |
|
|
| ROS |
|
-1362.77 | -298.59 | 356.41% |
|
|
| ROCE |
|
-28.9 | 3.17 | -1010.96% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.0147 | 0.94 | -101.56% | -0.0166 | -11.45% |
| Nеt Debt/Ebitda |
|
0.21 | 1.04 | -79.9% |
|
|
| Debt/Ratio |
|
0.004 | 0.18 | -97.78% |
|
|
| Debt/Equity |
|
0.0611 | 1.62 | -96.23% |
|
|
| Debt/Net Income |
|
-0.0175 | -1.65 | -98.94% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.53 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.82 | -100% | ||
| DSI |
|
0 | 0.21 | -100% |
|
|
| Average dividend growth |
|
0 | 2.29 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.52 | -100% |
|
|
| Average percentage for payments |
|
0 | 58.77 | -100% |
|
|
| Difference from average difference in sector |
|
-0.53 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
315.67 | -99.58 | -417% | ||
| Growth impulse Ebitda in 5 years |
|
32.27 | -152.61 | -121.15% | ||
| Growth impulse Net Income in 5 years |
|
13.44 | -115.25 | -111.66% | ||
| Growth impulse FCF in 5 years |
|
21.56 | -161.2 | -113.37% | ||
| Growth impulse EPS in 5 years |
|
-90.66 | -106.31 | -14.72% |
IP Score
3.52/10
